BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 03, 2013
 |  BC Week In Review  |  Company News  |  Deals

Okairos, GlaxoSmithKline deal

GlaxoSmithKline acquired vaccine company Okairos for €250 million ($323 million) in cash. GSK said it will use Okairos' adenovirus vector technology, which is based on replication-incompetent adenoviral vectors derived from non-human primates, to develop prophylactic and therapeutic T cell vaccines. The vectors are not recognized by pre-existing neutralizing antibodies...

Read the full 223 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >